Heat Biologics Provides Corporate Update And Reports Third Quarter 2016 Financial Results

Published: Nov 11, 2016

DURHAM, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, reported its financial results and provided a general business update for the third quarter and nine months ended September 30, 2016.

“We look forward to reporting top-line data in both our bladder and lung cancer trials within the next few weeks,” commented Jeff Wolf, Heat’s Founder and CEO. “Our results come on the heels of encouraging interim study findings from our Phase 1b trial evaluating HS-110 in combination with the Bristol-Myers Squibb anti-PD-1 checkpoint inhibitor, nivolumab. Our data in lung cancer suggest HS-110 may improve response rates for patients with ‘cold tumors’ who typically have lower response rates to checkpoint inhibitor monotherapy. We are also encouraged by our early data in bladder cancer that suggest we are activating a robust antigen-specific immune response.

Back to news